Curia and Carterra Partner on Biologics Symposium to Further Biotechnology Research in the Pacific Northwest
2024年5月9日 - 10:00PM
Curia, a leading contract research, development and manufacturing
organization and Carterra Inc., the world leader in label-free high
throughput antibody and small molecule drug discovery, today
announced their partnership in hosting a high-throughput biologics
symposium slated for May 31 at the Residence Inn at Marriott in
Seattle, Washington.
The purpose of the collaboration is to promote the rising
biotech focus within the Pacific Northwest region of the U.S and
Canada. The symposium will bring together all levels of scientific
leadership from the biotech and pharma communities.
"We are thrilled to be partnering with Carterra to organize this
antibody discovery symposium, bringing the Pacific Northwest
biotech community together and sharing the latest advances in
antibody discovery," said Steve Lavezoli, Vice President of
Biologics at Curia. "We are also looking forward to sharing our
optimal, high-quality and accelerated antibody discovery workflows
to first-to-human antibody discovery, development and clinical
manufacturing. Antibodies discovered and/or engineered with Curia’s
platform technology are in the clinic and we have over 230
successful antibody discovery campaigns performed for the biotech
community."
Speed, scientific expertise and efficiency can surmount the high
attrition rates of early antibody discovery and achieve
first-to-market delivery of new therapeutics. The symposium will
highlight Curia’s technology platform and integrated services with
a focus on the development of enhanced mouse systems for antibody
generation and high-throughput single B cell screening. The
combination of next generation sequencing (NGS) and rapid
recombinant production of milligram to gram quantities of purified
monoclonal antibody (mAb) significantly accelerates identification
of development candidate leads.
Since 2017, Carterra has been selling its powerful LSA®
high-throughput biosensor to analyze and characterize antibodies
using Surface Plasmon Resonance (SPR). With the launch of its LSAXT
platform last year, Carterra now offers products that can perform
small molecule analysis as well as antibody discovery. The LSA
platform has been profiled in several peer-reviewed papers in
Science, Nature and Cell, detailing the path of multiple
therapeutics entering clinical trials. At the symposium, several
leading scientists in biopharma will be sharing their insights into
their specific areas of drug discovery and will highlight the
transformative impact of integrating HT-SPR technology, AI/ML and
other new technologies.
“We are excited to be partnering with Curia on our symposium.
Carterra symposia are scientific events that we host each year
throughout the U.S. and Europe,” stated Chris M. Silva, Vice
President of Marketing and Product at Carterra. “These symposia
help us to share the latest technology advancements and important
data generated from the workflows of scientists using Carterra’s
label-free platforms. Coming to the Pacific Northwest is an
opportunity to create a deeper understanding of the technology in
pharma and biotechs in this region.”
Click here to RSVP for the event. Registration is required as
seating is limited.
About Curia:Curia is a Contract Development and
Manufacturing Organization (CDMO) with over 30 years of experience,
an integrated network of 27 global sites and over 3,500 employees
partnering with Biopharmaceutical customers to bring life-changing
therapies to market. Our biologics and small molecules offerings
span discovery through commercialization, with integrated
regulatory and analytical capabilities. Our scientific and process
experts and state-of-the-art facilities deliver best-in-class
experience across drug substance and drug product manufacturing.
From curiosity to cure, we deliver every step to improve patients’
lives. Visit us at curiaglobal.com.
About Carterra, Inc.:Carterra, Inc. is a
privately held company. Its HT-SPR technology provides
large-molecule and small-molecule drug discovery customers with
screening and characterization throughput and functionality that
scales with omics-level applications, condensing months of work
down to days. Our solutions have enabled multiple therapeutics and
breakthrough research and helped academic and translational
researchers and biopharmaceutical companies in oncology,
immunology, neuroscience, and more. Carterra is based
in Salt Lake City, Utah, and has Customer Experience Centers
in San Francisco, Salt Lake
City, Boston, Manchester, England, and Munich,
Germany. Carterra products are available
in Asia-Pacific and Oceania through our exclusive
distributor, Revvity. To learn more,
visit www.carterra-bio.com or connect with us on LinkedIn
or X (Twitter).
Curia Contact Information:Viana Bhagan+1 518
512 2111corporatecommunications@CuriaGlobal.com
Carterra Media Contact:Cheri Salazar(408)
594-9400csalazar@carterra-bio.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/020a0a28-86f0-4f6c-96f2-0eaa01c82784